Article

A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic Screen

2019-03-27

Abstract excerpt

We mutated the Focal Adhesion Kinase (FAK) catalytic domain to inhibit binding of the chaperone, Cdc37 and ATP, mimicking the actions of a FAK kinase inhibitor. We re-expressed mutant and wild-type FAK in squamous cell carcinoma (SCC) cells from which endogenous FAK had been deleted, genetically fixing one axis of a FAK inhibitor combination high-content phenotypic screen to discover drugs that may synergize with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 10ead922-6fa3-5ac7-b7df-c2c529cc9841
DOI: 10.1101/590802

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic ScreenDOI 10.1101/590802Read

A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic ScreenSemantic proximity Read

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitorsSemantic proximity Read

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetics effectsSemantic proximity Read

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergismsSemantic proximity Read

High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery.Semantic proximity Read

A Rational Drug Combination Design to Inhibit Epithelial-Mesenchymal Transition in a Three-Dimensional MicroenvironmentSemantic proximity Read

Image-based phenotypic profiling of a chemogenomic screening library identifies novel druggable targets in the EGFR-pathwaySemantic proximity Read

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.Semantic proximity Read

FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent mannerSemantic proximity Read

Precision Targeting Strategies in Cancer Therapy: Focusing on Synthetic Lethality with FAK InhibitionSemantic proximity Read

Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric CancerSemantic proximity Read